What Happened? Shares of scientific consulting firm Exponent (NASDAQ:EXPO) jumped in the afternoon session after UBS raised ...

If you are wondering whether Exponent is a bargain or a trap at today’s price, you are not alone. This breakdown is designed to help you see what the market might be missing. The stock has slipped 1.6 ...

Exponent’s revenue has grown at a CAGR of 6% while EBITDA has at 8%. This has been driven by its fantastic business model and industry tailwinds. Exponent provides highly complex consulting services ...

Scientific consulting firm Exponent (NASDAQ:EXPO) will be reporting earnings this Thursday afternoon. Here’s what to expect. Exponent beat analysts’ revenue expectations by 2.1% last quarter, ...

After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which ...

Exponent's (NASDAQ:EXPO) stock up by 2.8% over the past month. Given its impressive performance, we decided to study the company's key financial indicators as a company's long-term fundamentals ...

Earnings from consulting firm Exponent (NASDAQ: EXPO) came in below expectations, and the company continues to see challenges heading into 2024. Investors are moving to the sidelines, sending shares ...

Prosper Stars & Stripes, a long/short equity fund, recently released its second quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund underperformed and generated a net ...

Fintel reports that on December 15, 2025, UBS maintained coverage of Exponent (NasdaqGS:EXPO) with a Neutral recommendation.

Scientific consulting firm Exponent (NASDAQ:EXPO) will be announcing earnings results this Thursday afternoon. Here’s what to look for. Exponent beat analysts’ revenue expectations by 1.5% last ...